The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan).
 
Eri Sugiyama
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuaki Kobayashi
No Relationships to Disclose
 
Hiromi Aono
No Relationships to Disclose
 
Masato Shingyoji
No Relationships to Disclose
 
Katsuyuki Hotta
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical
 
Akimasa Sekine
No Relationships to Disclose
 
Satoshi Hara
No Relationships to Disclose
 
Naoki Furuya
No Relationships to Disclose
 
Taku Nakagawa
No Relationships to Disclose
 
Hirofumi Nakazaki
No Relationships to Disclose
 
Taishi Harada
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Chugai Pharma; Nippon Boehringer Ingelheim
 
Saori Takata
No Relationships to Disclose
 
Norio Okamoto
Speakers' Bureau - AstraZeneca Japan
 
Kageaki Taima
No Relationships to Disclose
 
Keisuke Tomii
Honoraria - AstraZeneca; Boehringer Ingelheim
Consulting or Advisory Role - Lilly
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst)
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Life Technologies; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
Research Funding - Abbvie; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda